Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.55 |
| ▸ | SYK | P43405 | 6/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303878 | 0.99 | CSF1R (0.58) | CSF1RPDE4BSYKAURKBZAP70 | |
| SCHEMBL5468596 | 0.86 | CSF1R (0.56) | CSF1RPDE4BAURKB | |
| SCHEMBL12115508 | 0.83 | PDE4B (0.55) | CSF1RPDE4BSYKAURKBZAP70 | |
| SCHEMBL13754028 | 0.77 | PDE4B (0.73) | CSF1RPDE4B | |
| SCHEMBL12115504 | 0.77 | CSF1R (0.74) | CSF1RPDE4BAURKBEGFRERBB2 | |
| Ammonia Solution, Strong SCHEMBL5809043 | 0.77 | SYK (0.51) | SYKAURKBZAP70KCNH2 | |
| SCHEMBL5808384 | 0.77 | TP53 (0.57) | PDE4BAURKB | |
| SCHEMBL4951411 | 0.76 | CSF1R (0.58) | CSF1RPDE4BSYKAURKBZAP70 | |
| SCHEMBL5474414 | 0.75 | MAPT (0.56) | PDE4BSYKZAP70 | |
| SCHEMBL4627527 | 0.75 | PDE4B (0.62) | CSF1RPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1673345-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | CSF1R 3981/4885PDE4B 1/4885SYK 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.